• Capital increase of €5.3 million in gross proceeds (€4.75 million cash and €0.55 million Hexagon debt roll) through the issuance of 101,923,092 new shares and warrants giving right to 127,403,865 new shares
• Obesity trial, through a combination of proceeds from the offering & existing credit lines, now fully funded to topline readout in half-year 2028
• Placement balanced between US & European institutional investors (62% & 38% respectively)
• Use of proceeds: prosecution of obesity trial in US, EU and Brazil & extension of the company’s cash runway until at least the first quarter of 2028
• All warrants from the March 2026 capital increase exercised for total proceeds of €2.8 million
• Hexagon credit line outstanding balance reduced from €1.2 million to €0.65 million through rollover into the capital increase
• 350,132,497 shares outstanding post offering and a cash /cash equivalent position of €8,9 million
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer